

Guillaume Bossis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3999664/publications.pdf>

Version: 2024-02-01

29
papers

1,983
citations

430874

18
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

3014
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery and Mechanism of Action of Small Molecule Inhibitors of Ceramidases**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	13.8	19
2	The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias. <i>Haematologica</i> , 2022, 107, 2562-2575.	3.5	13
3	Trim39 regulates neuronal apoptosis by acting as a SUMO-targeted E3 ubiquitin-ligase for the transcription factor NFATc3. <i>Cell Death and Differentiation</i> , 2022, 29, 2107-2122.	11.2	4
4	SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies. <i>Molecules</i> , 2021, 26, 828.	3.8	46
5	SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells. <i>Nature Communications</i> , 2021, 12, 4582.	12.8	17
6	Staphylococcus aureus Decreases SUMOylation Host Response to Promote Intramacrophage Survival. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8108.	4.1	7
7	1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are broad-spectrum metallo- β -lactamase inhibitors with re-sensitization activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113873.	5.5	16
8	Regulation of Viral Restriction by Post-Translational Modifications. <i>Viruses</i> , 2021, 13, 2197.	3.3	8
9	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. <i>Cancers</i> , 2020, 12, 2874.	3.7	3
10	Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1233, 29-54.	1.6	11
11	Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies. <i>Life Science Alliance</i> , 2020, 3, e201900577.	2.8	13
12	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 5191-5203.	0.9	45
13	The SUMO Pathway in Hematomalignancies and Their Response to Therapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3895.	4.1	29
14	Particulate matter-induced senescence of skin keratinocytes involves oxidative stress-dependent epigenetic modifications. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-14.	7.7	71
15	Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. <i>Cancer Research</i> , 2018, 78, 2601-2613.	0.9	45
16	SUMO Safeguards Somatic and Pluripotent Cell Identities by Enforcing Distinct Chromatin States. <i>Cell Stem Cell</i> , 2018, 23, 742-757.e8.	11.1	105
17	Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	27
18	Production and Purification of Recombinant SUMOylated Proteins Using Engineered Bacteria. <i>Methods in Molecular Biology</i> , 2016, 1475, 55-65.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Detection of Protein-Protein Interactions and Posttranslational Modifications Using the Proximity Ligation Assay: Application to the Study of the SUMO Pathway. <i>Methods in Molecular Biology</i> , 2016, 1449, 279-290.	0.9	27
20	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. <i>Cell Reports</i> , 2014, 7, 1815-1823.	6.4	86
21	Sumoylation inhibits α -synuclein aggregation and toxicity. <i>Journal of Cell Biology</i> , 2011, 194, 49-60.	5.2	210
22	SUMOylation Regulates the Transcriptional Activity of JunB in T Lymphocytes. <i>Journal of Immunology</i> , 2008, 180, 5983-5990.	0.8	52
23	SUMO under stress. <i>Biochemical Society Transactions</i> , 2008, 36, 874-878.	3.4	154
24	E4F1 Is an Atypical Ubiquitin Ligase that Modulates p53 Effector Functions Independently of Degradation. <i>Cell</i> , 2006, 127, 775-788.	28.9	214
25	Regulation of SUMOylation by Reversible Oxidation of SUMO Conjugating Enzymes. <i>Molecular Cell</i> , 2006, 21, 349-357.	9.7	323
26	SUMO: regulating the regulator. <i>Cell Division</i> , 2006, 1, 13.	2.4	130
27	Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation. <i>Molecular and Cellular Biology</i> , 2005, 25, 6964-6979.	2.3	172
28	A Fluorescence Resonance Energy Transfer-Based Assay to Study SUMO Modification in Solution. <i>Methods in Enzymology</i> , 2005, 398, 20-32.	1.0	40
29	SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. <i>Journal of Cell Biology</i> , 2004, 165, 767-773.	5.2	89